PURPOSE: To determine the global metabolomic profile as measured in circulating plasma from surviving and non-surviving patients with community-acquired pneumonia (CAP) and sepsis. METHODS: Random, outcome-stratified case-control sample from a prospective study of 1,895 patients hospitalized with CAP and sepsis. Cases (n = 15) were adults who died before 90 days, and controls (n = 15) were adults who survived, matched on demographics, infection type, and procalcitonin. We determined the global metabolomic profile in the first emergency department blood sample using non-targeted mass-spectrometry. We derived metabolite-based prognostic models for 90-day mortality. We determined if metabolites stimulated cytokine production by differentiated Thp1 monocytes in vitro, and validated metabolite profiles in mouse liver and kidney homogenates at 8 h in cecal ligation and puncture (CLP) sepsis. RESULTS: We identified 423 small molecules, of which the relative levels of 70 (17 %) were different between survivors and non-survivors (p ≤ 0.05). Broad differences were present in pathways of oxidative stress, bile acid metabolism, and stress response. Metabolite-based prognostic models for 90-day survival performed modestly (AUC = 0.67, 95 % CI 0.48, 0.81). Five nucleic acid metabolites were greater in non-survivors (p ≤ 0.05). Of these, pseudouridine increased monocyte expression of TNFα and IL1β versus control (p < 0.05). Pseudouridine was also increased in liver and kidney homogenates from CLP mice versus sham (p < 0.05 for both). CONCLUSIONS: Although replication is required, we show the global metabolomic profile in plasma broadly differs between survivors and non-survivors of CAP and sepsis. Metabolite-based prognostic models had modest performance, though metabolites of oxidative stress may act as putative damage-associated molecular patterns.
RCT Entities:
PURPOSE: To determine the global metabolomic profile as measured in circulating plasma from surviving and non-surviving patients with community-acquired pneumonia (CAP) and sepsis. METHODS: Random, outcome-stratified case-control sample from a prospective study of 1,895 patients hospitalized with CAP and sepsis. Cases (n = 15) were adults who died before 90 days, and controls (n = 15) were adults who survived, matched on demographics, infection type, and procalcitonin. We determined the global metabolomic profile in the first emergency department blood sample using non-targeted mass-spectrometry. We derived metabolite-based prognostic models for 90-day mortality. We determined if metabolites stimulated cytokine production by differentiated Thp1 monocytes in vitro, and validated metabolite profiles in mouse liver and kidney homogenates at 8 h in cecal ligation and puncture (CLP) sepsis. RESULTS: We identified 423 small molecules, of which the relative levels of 70 (17 %) were different between survivors and non-survivors (p ≤ 0.05). Broad differences were present in pathways of oxidative stress, bile acid metabolism, and stress response. Metabolite-based prognostic models for 90-day survival performed modestly (AUC = 0.67, 95 % CI 0.48, 0.81). Five nucleic acid metabolites were greater in non-survivors (p ≤ 0.05). Of these, pseudouridine increased monocyte expression of TNFα and IL1β versus control (p < 0.05). Pseudouridine was also increased in liver and kidney homogenates from CLPmice versus sham (p < 0.05 for both). CONCLUSIONS: Although replication is required, we show the global metabolomic profile in plasma broadly differs between survivors and non-survivors of CAP and sepsis. Metabolite-based prognostic models had modest performance, though metabolites of oxidative stress may act as putative damage-associated molecular patterns.
Authors: Jessica R Adams Wilson; Alessandro Morandi; Timothy D Girard; Jennifer L Thompson; Chad S Boomershine; Ayumi K Shintani; E Wesley Ely; Pratik P Pandharipande Journal: Crit Care Med Date: 2012-03 Impact factor: 7.598
Authors: Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan Journal: Nature Date: 2009-02-12 Impact factor: 49.962
Authors: Ricard Ferrer; Antonio Artigas; Mitchell M Levy; Jesús Blanco; Gumersindo González-Díaz; José Garnacho-Montero; Jordi Ibáñez; Eduardo Palencia; Manuel Quintana; María Victoria de la Torre-Prados Journal: JAMA Date: 2008-05-21 Impact factor: 56.272
Authors: B Chernow; H R Alexander; R C Smallridge; W R Thompson; D Cook; D Beardsley; M P Fink; C R Lake; J R Fletcher Journal: Arch Intern Med Date: 1987-07
Authors: Jochen Hinkelbein; Robert E Feldmann; Anna Peterka; Charlotte Schubert; Dominik Schelshorn; Martin H Maurer; Armin Kalenka Journal: Curr Neurovasc Res Date: 2007-11 Impact factor: 1.990
Authors: Junru Wu; Anthony Cyr; Danielle Gruen; Tyler Lovelace; Panayiotis Benos; Tianmeng Chen; Francis Guyette; Mark Yazer; Brian Daley; Richard Miller; Brian Harbrecht; Jeffrey Claridge; Herb Phelan; Brian Zuckerbraun; Matthew Neal; Pär Johansson; Jakob Stensballe; Rami Namas; Yoram Vodovotz; Jason Sperry; Timothy Billiar; PAMPer Study Group Journal: Res Sq Date: 2021-01-08
Authors: Michael A Puskarich; Michael A Finkel; Alla Karnovsky; Alan E Jones; Julie Trexel; Brooke N Harris; Kathleen A Stringer Journal: Ann Am Thorac Soc Date: 2015-01
Authors: Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy Journal: Expert Rev Vaccines Date: 2019-02-11 Impact factor: 5.217